Single-stranded deoxyribonucleic acid (ssDNA) aptamer targeting human highly metastatic hepatoma carcinoma cell and application thereof

Abstract

The invention discloses a single-stranded deoxyribonucleic acid (ssDNA) aptamer targeting human highly metastatic hepatoma carcinoma cell and an application of the ssDNA aptamer, and relates to the field of diagnosis and treatment of the recurrence and metastasis of the hepatocellular carcinoma, so that the high-efficient novel specific molecules are provided for the diagnosis and treatment of the recurrence and metastasis of the hepatocellular carcinoma. According to the invention, a subtractive cell-SELEX technology is applied, two hepatoma carcinoma cell systems with same genetic background and obviously different metastatic potentials are a subtractive target and a screening target, respectively, and the hepatoma carcinoma cell systems are MHCC97-L (low metastasis) and HCCLM9 (high metastasis), so that the ssDNA aptamer is capable of specifically recognizing the highly metastatic potential hepatoma carcinoma cell HCCLM9. The aptamer is a single-stranded DNA molecular probe capableof specially combining with a surface of a human highly metastatic hepatoma carcinoma cell membrane, and a nucleotide sequence of aptamer is represented by SEQ ID No.1. The aptamer is expected to play an important role in preparation of a reagent for diagnosing or treating the hepatocellular carcinoma.

Description

technical field

[0001] The invention relates to the technical field of diagnosis and treatment of liver cancer metastasis and recurrence, in particular to a single-stranded DNA aptamer targeting human high-metastatic liver cancer cells and its application, which can be used for targeted diagnosis and treatment of liver cancer metastasis and recurrence. Background technique

[0002] Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world, accounting for 6% of all malignant tumors. China is the country with the highest mortality rate of liver cancer in the world, accounting for 53% of the total number of deaths from liver cancer in the world. Become the second cause of death of malignant tumors. Although great progress has been made in the diagnosis, treatment and basic research of liver cancer in recent decades, overall, the prognosis of liver cancer has not been significantly improved, and the 5-year survival rate is only about 5%. At present,...

Images